Sydney, Australia 11 October 2018 – Clarity Pharmaceuticals, an Australian radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that Prof Jason S. Lewis has joined their scientific advisory board. Jason S. Lewis, PhD, serves as Vice Chair for Research in the Department of Radiology at Memorial Sloan Kettering Cancer Center (MSK),…
Clarity Pharmaceuticals was featured in AUSinnovates, a media project driven by gemaker that aims to stimulate research and innovation in Australia. The article sheds light on the story behind Clarity’s SAR Technology, discusses Clarity’s product pipeline and talks about the benefits of a collaborative approach to drug development. Read the full article here: https://www.ausinnovates.com.au/clarity/
Sydney, Australia 13 September 2018 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of cancer, cardiovascular disease and fibrosis, has received a strategic investment of $5 million from GenesisCare, the largest private provider of cancer treatment in Australia and Europe. The funds will go towards the development of Clarity’s clinical pipeline, aligning with…
Sydney, Australia 23 August 2018 – Clarity Pharmaceuticals, an Australian radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that Dr Gillies O’Bryan-Tear has joined their scientific advisory board. Dr O’Bryan-Tear joined the pharmaceutical industry in 1986 where he has spent 30 years in clinical development, medical management and commercial roles.…
Sydney, Australia 10 July 2018 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that site activation at Royal North Shore Hospital in Sydney has been completed and recruitment has commenced for its SARTATE™ clinical trial. Clarity’s SARTATE™ trial is a Peptide Receptor Radionuclide Therapy clinical trial…
Sydney, Australia 6 June 2018 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the appointment of Michelle Parker as Head of Clinical Operations at Clarity. Michelle has enjoyed a diverse career spanning across Nuclear Medicine/PET and pharmaceutical industries, both locally and abroad over the last 20…
Clarity Pharmaceuticals was featured in Australasian BioTechnology, the journal of Ausbiotech, Australia’s life sciences industry organisation. The article, which was written by Clarity’s Lisa Sadetskaya, discusses the issues associated with gender in the life sciences and the benefits of creating gender-diverse teams. The article features Clarity as a case study, discussing practices that encourage…
Clarity Pharmaceuticals was featured in Gamma Gazette, a journal and newsletter issued by the Australian and New Zealand Society of Nuclear Medicine (ANZSNM), which provides a unique educational resource for all those working in the field of nuclear medicine as well as a means of publication for individual members’ research work. The article discusses…
Sydney, Australia 20 April 2018 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it was invited to give oral presentations and presentations of their posters at the upcoming 12th Congress of the World Federation of Nuclear Medicine and Biology (WFNMB) in Melbourne. Clarity’s CEO, Dr…
Sydney, Australia 21 February 2018 – Clarity Pharmaceuticals, an Australian radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that Professor Andreas Kjaer has joined their scientific advisory board. Andreas Kjaer is a professor at the University of Copenhagen and is chief physician and head of research at the Department of…